Project Grant R44CA314644
Award Date 8/19/26
Completion Date 7/31/27
Dollars Obligated $404K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Farmington, CT 06032, USA
Similar Awards
- The National Cancer Institute awarded The University of Chicago $692,063 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to advance early colorectal cancer diagnosis and risk stratification using DNA methylation markers. The funded work develops blood-based biomarkers to detect colorectal cancer and advanced adenomas through cell-free DNA analysis, addressing the gap in sensitivity of existing tools such as MSEPT9, Cologuard, and Shield. The research...
- The National Cancer Institute awarded Senticell LLC $399,995 for a Phase I Small Business Technology Transfer (STTR) project grant on September 1, 2026, to develop an red blood cell–based liquid biopsy platform for detecting circulating tumor DNA in early-stage non-small cell lung cancer. The recipient will establish the biological and clinical performance of RBC-bound tumor DNA detection using vertebrate animal models of KRAS- and EGFR-driven lung cancer to characterize in vivo kinetics of...
- The National Cancer Institute awarded a cooperative agreement totaling $738,675 to Beckman Research Institute of the City of Hope on March 16, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an exosome-based liquid biopsy assay for non-invasive early detection of colorectal adenomas and cancers. The project addresses the limitation that current fecal immunochemical testing (FIT) shows declining sensitivity for early-stage colorectal cancer and advanced...
- The National Cancer Institute awarded Northwestern University $1,297,466 under Project Grant R01CA303254 on August 12, 2026, to develop nanoscale spectroscopy methods for early colorectal cancer detection and phenotypic analysis through the Cancer Detection and Diagnosis Research program (CFDA 93.394). The project addresses the limitations of current non-endoscopic colorectal cancer screening tests by integrating three innovations: leveraging field carcinogenesis—the histologically normal,...
- The National Cancer Institute awarded Omicxhealth, Inc. $405,305 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394, Assistance Listing Project Grant R43CA310377) to develop OMICXSCREEN, an artificial intelligence and machine learning-powered blood test for early detection of hepatocellular carcinoma and esophageal cancer. OMICXSCREEN uses cell-free DNA methylation profiling via whole-genome bisulfite sequencing paired with a patent-pending...
- The National Cancer Institute awarded the University of California, San Diego $671,226 on May 15, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop engineered native bacteria—host-derived E. coli strains—as a microbial platform for durable, targeted delivery of therapeutic molecules to the gut to prevent or treat colorectal cancer. The research addresses a critical gap in microbial therapies for colorectal cancer, which the American Cancer Society projects will account...
- The National Cancer Institute awarded The Institute For Cancer Research a $263,670 cooperative agreement on May 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and clinically translate a urine-based biomarker for detecting residual disease in bladder cancer patients scheduled for radical cystectomy. The award funds development of a noninvasive test for assessment of cancerous tumors (NTACT) that identifies residual bladder disease by detecting...
- The National Science Foundation awarded Caleo Biotechnologies, Inc. $289,435 on July 1, 2026, under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop patient-derived, multicellular tissue models for studying colitis-associated colorectal cancer. The project will generate self-assembling tissue systems that integrate epithelial, stromal, and immune compartments to reproduce inflammation-driven tumor initiation and early progression. The models aim to reduce...
- The National Cancer Institute awarded Cold Spring Harbor Laboratory $704,182 under the Cancer Biology Research program (CFDA 93.396) on June 16, 2026, to dissect non-mutational mechanisms driving benign-to-malignant transition in colorectal cancer. The project uses a novel mouse model that stepwise acquires mutations mirroring human colorectal cancer progression—starting with APC knockout to initiate benign polyps, then inducing KRAS G12V and TP53 loss in rare cells within established polyps...
- The National Cancer Institute awarded $1,057,841 to Pathware Inc. on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) as a Small Business Innovation Research Direct-to-Phase II grant (R44CA302204). Pathware is developing an automated imaging platform combining coded ptychography with artificial intelligence algorithms to evaluate the diagnostic adequacy of unstained lung biopsy samples at the point of care. The system provides rapid on-site evaluation...